FINAL DEADLINE ALERT: Brower Piven Reminds Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In Myriad Genetics, Inc. (NASDAQ: MYGN) To Contact The Firm
STEVENSON, Md., June 12, 2018 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Utah on behalf of purchasers of Myriad Genetics, Inc. (NASDAQ:MYGN) (“Myriad” or the “Company”) securities during the period between August 13, 2014 and March 12, 2018, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until June 19, 2018 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in Myriad securities during the Class Period. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No class has yet been certified in the above action.
The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that Myriad was submitting false or otherwise improper claims for payment under Medicare and Medicaid for the Company’s hereditary cancer testing which would subject Myriad to heightened regulatory scrutiny and/or enforcement action, and its revenues from its hereditary cancer testing were in part the product of improper conduct and unlikely to be sustainable.
According to the complaint, following a March 12, 2018 announcement that the Company had received a subpoena from the Department of Health and Human Services in connection with an investigation into possible false or otherwise improper claims submitted for payment under Medicare and Medicaid relating to Myriad’s hereditary cancer testing, the value of Myriad shares declined significantly.
If you have suffered a loss in excess of $100,000 from investment in Myriad securities purchased on or after August 13, 2014 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please contact Brower Piven either by email at firstname.lastname@example.org or by telephone at (410) 415-6616.
Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s. If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice. You need take no action at this time to be a member of the class.
CONTACT: Charles J. PivenBrower Piven, A Professional Corporation1925 Old Valley RoadStevenson, Maryland 21153Telephone: 410-415-6616 email@example.com